This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Idera Announces Initiation Of Lupus Clinical Development Program With Phase 1 Trial Of IMO-8400

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced the initiation of dosing in a Phase 1 trial of IMO-8400. IMO-8400 is an antagonist of Toll-like receptors (TLRs) 7, 8 and 9, and is the second clinical candidate in Idera’s autoimmune disease program. Idera expects to develop IMO-8400 for the treatment of lupus as an initial indication. Idera also announced the presentation of preclinical data on IMO-8400 at the American College of Rheumatology that support its potential to treat autoimmune diseases through inhibition of Th1, Th17, and inflammasome activation.

“We are pleased to have initiated the clinical development of IMO-8400 in our lupus program,” said Robert Arbeit, MD, Vice President of Clinical Development at Idera. “IMO-8400 provides a novel approach to the treatment of lupus, by blocking signaling through Toll-like receptors. In preclinical studies, lupus-prone mice treated with IMO-8400 demonstrated suppression of multiple pro-inflammatory cytokines, inhibition of auto-antibody production, and improvement in renal function, all of which are components of SLE pathophysiology. These changes are consistent with the intended mechanism of action of this candidate.”

“The next objectives in our autoimmune disease programs are to have top-line data for some of the endpoints from our Phase 2 trial of IMO-3100 in patients with psoriasis by year end 2012 and to complete our Phase 1 trial of IMO-8400,” said Dr. Sudhir Agrawal, Chief Executive Officer of Idera. “Our recent raise of $7 million, in addition to the $8.5 million that we had on hand at the end of the third quarter, we expect will allow us to meet these near-term objectives.”

The goals of the Phase 1 trial in the clinical development of IMO-8400 are to assess the safety and pharmacodynamic activity of IMO-8400 in healthy subjects. A total of 30 healthy subjects are scheduled to receive single or multiple ascending doses of IMO-8400. Data from this study are expected to be available during Q2 2013. Following successful completion of the Phase 1 study and additional funding, the Company expects to initiate a Phase 2 clinical trial of IMO-8400 in lupus patients.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,131.86 +47.37 0.28%
S&P 500 2,014.89 +15.91 0.80%
NASDAQ 4,838.6430 +8.1730 0.17%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs